MedTrace Logo

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-02-25

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Diffuse Intrinsic Pontine Glioma

Interventions

DRUG

Panobinostat Nanoparticle Formulation MTX110

Given IT

DRUG

Convection-Enhanced Delivery (CED)

Undergo CED

Sponsors & Collaborators

  • Midatech Pharma US Inc.

    collaborator INDUSTRY

  • Pacific Pediatric Neuro-Oncology Consortium

    collaborator OTHER

  • Sabine Mueller, MD, PhD

    lead OTHER

Principal Investigators

  • Sabine Mueller, M.D. · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566199 on ClinicalTrials.gov